S M Mansour Haeryfar Selected Research

S M Mansour Haeryfar Research Topics

Disease

16	Neoplasms (Cancer) 05/2022 - 05/2002
11	Infections 01/2020 - 01/2005
7	Septic Shock (Toxic Shock Syndrome) 05/2018 - 06/2009
3	Virus Diseases (Viral Diseases) 01/2020 - 02/2011
3	Cytokine Release Syndrome 06/2017 - 01/2017
2	Sepsis (Septicemia) 01/2021 - 01/2015
2	Human Influenza (Influenza) 01/2020 - 01/2008
2	Colonic Neoplasms (Colon Cancer) 01/2019 - 01/2014
2	Scarlet Fever 09/2017 - 05/2014
2	Arthritis (Polyarthritis) 07/2012 - 10/2010
2	Rheumatoid Arthritis 07/2012 - 10/2010
2	Influenza in Birds (Avian Flu) 03/2010 - 11/2009
2	Mastocytoma 03/2003 - 05/2002
1	Ascites 05/2022
1	Ovarian Neoplasms (Ovarian Cancer) 05/2022
1	Ovarian Epithelial Carcinoma 05/2022
1	COVID-19 12/2021
1	Vesicular Stomatitis 12/2021
1	Hypersensitivity (Allergy) 01/2021
1	Superinfection 01/2020
1	Thymoma (Thymic Carcinoma) 10/2019
1	Skin Neoplasms (Skin Cancer) 01/2019
1	Inflammation (Inflammations) 01/2019
1	Polyps 01/2019
1	Leishmaniasis 01/2018
1	Disease Progression 01/2018
1	Gram-Positive Bacterial Infections 01/2017
1	Acquired Immunodeficiency Syndrome (AIDS) 11/2016
1	Communicable Diseases (Infectious Diseases) 10/2016
1	Abscess 09/2014
1	Bacteremia 09/2014
1	Cowpox 01/2005

Drug/Important Bio-Agent (IBA)

10	SuperantigensIBA 01/2020 - 06/2009
7	LigandsIBA 05/2022 - 03/2008
5	Proteins (Proteins, Gene)FDA Link 01/2019 - 07/2012
4	CytokinesIBA 05/2022 - 01/2008
4	VaccinesIBA 12/2021 - 01/2005
4	GlycolipidsIBA 10/2016 - 03/2008
4	AntigensIBA 10/2016 - 11/2009
3	EpitopesIBA 01/2020 - 01/2008
2	ChemokinesIBA 01/2021 - 09/2014
2	Antiviral Agents (Antivirals)IBA 01/2020 - 01/2019
2	AntibodiesIBA 01/2020 - 09/2017
2	Peptides (Polypeptides)IBA 01/2019 - 11/2017
2	Interleukin-17 (Interleukin 17)IBA 12/2018 - 01/2017
2	Histocompatibility Antigens Class IIIBA 05/2018 - 05/2014
2	Virulence Factors (Pathogenicity Factors)IBA 09/2017 - 05/2014
2	staphylococcal enterotoxin BIBA 09/2017 - 06/2009
2	nef Gene Products (nef Gene Product)IBA 01/2017 - 11/2016
2	HLA-DR4 Antigen (HLA DR4 Antigen)IBA 09/2014 - 07/2012
2	ExotoxinsIBA 05/2014 - 06/2009
2	CitrullineIBA 07/2012 - 10/2010
2	Galactosylceramides (Galactocerebrosides)IBA 02/2011 - 03/2008
2	Hemagglutinins (Hemagglutinin)IBA 03/2010 - 11/2009
1	RNA (Ribonucleic Acid)IBA 05/2022
1	COVID-19 VaccinesIBA 12/2021
1	Neutralizing AntibodiesIBA 12/2021
1	SolutionsIBA 12/2021
1	Histocompatibility Antigens Class IIBA 01/2021
1	HaptensIBA 01/2021
1	Granzymes (Granzyme)IBA 10/2019
1	EstersIBA 01/2019
1	Peptide Hydrolases (Proteases)FDA Link 01/2019
1	6-carboxyfluorescein (carboxyfluorescein)IBA 01/2019
1	CateninsIBA 01/2019
1	5-(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)IBA 01/2019
1	Monoclonal AntibodiesIBA 11/2018
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 05/2018
1	TOR Serine-Threonine KinasesIBA 01/2018
1	MTOR InhibitorsIBA 01/2018
1	Pharmaceutical PreparationsIBA 01/2018
1	Bevacizumab (Avastin)FDA Link 12/2017
1	Cytokine Receptors (Cytokine Receptor)IBA 12/2017
1	Streptococcus pyogenes SpeA proteinIBA 09/2017
1	Immunoglobulins (Immunoglobulin)IBA 06/2017
1	Mucin-3IBA 06/2017
1	LipidsIBA 10/2016
1	Interleukin-12 (IL 12)IBA 09/2014
1	Interferon-gamma (Interferon, gamma)IBA 09/2014
1	Staphylococcal enterotoxin AIBA 09/2014
1	ToxoidsIBA 05/2014
1	erythrogenic toxinIBA 01/2014
1	Viral AntigensIBA 01/2014
1	Single-Chain AntibodiesIBA 01/2014
1	Ethylene Oxide (Oxirane)IBA 05/2013
1	polycaprolactoneIBA 05/2013
1	C-galactosylceramideIBA 07/2012
1	HLA Antigens (Human Leukocyte Antigens)IBA 07/2012
1	serum P-component (CIt)IBA 10/2010
1	Immunoglobulin G (IgG)IBA 10/2010
1	Fibrinogen (Factor I)FDA Link 10/2010
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 11/2009
1	Peptidoglycan (Murein)IBA 06/2009
1	Toll-Like Receptor 2IBA 06/2009

Therapy/Procedure

8	Immunotherapy 05/2022 - 03/2008
3	Therapeutics 01/2021 - 02/2011
1	Ligation 01/2021
1	Punctures 01/2021
1	Drug Therapy (Chemotherapy) 12/2017
1	Critical Care (Surgical Intensive Care) 01/2015